Lexeo Therapeutics, Inc. (LXEO): Total Liabilities
$22.02M
As of 2025-12-31
$19.84M
As of 2026-06-30
-4.1%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.02M | -26.8% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $30.10M | +14.6% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $26.27M | +5.1% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $25.00M | n/a | 2024-03-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $22.02M | -26.8% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $9.71M | -20.0% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $35.34M | -43.0% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $197.33M | -66.0% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| Alector, Inc. (ALEC) | 2025-12-31 | $262.59M | -23.1% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $61.55M | +61.7% |
Compare LXEO, TECX, IVVD, CHRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗